261 related articles for article (PubMed ID: 27188755)
1. Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study.
Ntelis K; Gkizas V; Filippopoulou A; Davlouros P; Alexopoulos D; Andonopoulos AP; Daoussis D
BMC Musculoskelet Disord; 2016 May; 17():213. PubMed ID: 27188755
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
3. Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s.
Olechowski B; Dalton RT; Khanna V; Ashby A; Vavyla M; Mariathas M; Harris S; Nicholas Z; Mahmoudi M; Curzen N
Cardiovasc Ther; 2018 Aug; 36(4):e12433. PubMed ID: 29682911
[TBL] [Abstract][Full Text] [Related]
4. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
5. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
[TBL] [Abstract][Full Text] [Related]
6. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics.
Hernandez-Suarez DF; Scott SA; Tomey MI; Melin K; Lopez-Candales A; Buckley CE; Duconge J
Ther Adv Cardiovasc Dis; 2017 Sep; 11(9):235-241. PubMed ID: 28675986
[TBL] [Abstract][Full Text] [Related]
7. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
Verdoia M; Schaffer A; Barbieri L; Cassetti E; Piccolo R; Galasso G; Marino P; Sinigaglia F; De Luca G
J Cardiovasc Pharmacol; 2014 Apr; 63(4):339-50. PubMed ID: 24336016
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
[TBL] [Abstract][Full Text] [Related]
9. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
Platelets; 2015; 26(6):545-51. PubMed ID: 25167467
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
11. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
12. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
[TBL] [Abstract][Full Text] [Related]
13. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
15. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
[TBL] [Abstract][Full Text] [Related]
16. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
Graff J; Harder S; Wahl O; Scheuermann EH; Gossmann J
Clin Pharmacol Ther; 2005 Nov; 78(5):468-76. PubMed ID: 16321613
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.
Jia LX; Qi GM; Liu O; Li TT; Yang M; Cui W; Zhang WM; Qi YF; Du J
Cardiovasc Drugs Ther; 2013 Dec; 27(6):521-30. PubMed ID: 23887740
[TBL] [Abstract][Full Text] [Related]
19. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity.
Alexopoulos D; Plakomyti TE; Xanthopoulou I
Int J Cardiol; 2012 Feb; 154(3):333-4. PubMed ID: 22075413
[No Abstract] [Full Text] [Related]
20. Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy.
Woo JS; Kim W; Jang HH; Kim JB; Kim WS; Kim KS
Am J Cardiol; 2014 Mar; 113(5):786-92. PubMed ID: 24388620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
